Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in Advanced Differentiated and Anaplastic Thyroid Neoplasms
NCT06235216Phase 2Recruiting
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Sep 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in differentiated thyroid cancer (DTC) and anaplastic thyroid cancer (ATC), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: Objective Response Rate at 42 months. Started Sep 2024; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
differentiated thyroid cancer (DTC)anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on NCT06235216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06235216.